LUX MED Onkologia – Szpital Szamocka
LUX MED Onkologia is a private Polish oncology hospital network operating six facilities across Warsaw and Łódź, providing NFZ-funded cancer diagnosis, robotic and surgical oncology, chemotherapy, immunotherapy, endoscopy, and rehabilitation under specialized BCU and CCU designations.
- Company typePrivate
- Founded2005
- HeadquartersWarszawa, Mazowieckie, Poland
- Headcount1–10
- GTM typeB2C
- OfferingServices
What LUX MED Onkologia – Szpital Szamocka does
LUX MED Onkologia sp. z o.o. is a private Polish oncology hospital network operating as a subsidiary of Grupa LUX MED, one of the largest private healthcare providers in Poland. The company runs six facilities across the Masovian and Łódź voivodeships: four hospitals in Warsaw (Szpital Szamocka, Szpital św. Wincentego, Szpital Fieldorfa, Szpital św. Elżbiety), one endotherapy center in Łódź, and a rehabilitation center in Warsaw. The network provides comprehensive cancer diagnosis and treatment under NFZ (Narodowy Fundusz Zdrowia) contracts, covering surgical oncology, clinical oncology and chemotherapy, immunotherapy, hormone therapy, drug programs, diagnostic imaging, endoscopic procedures, and psycho-oncological support. It holds specialist Breast Cancer Unit (BCU) and Colorectal Cancer Unit (CCU) designations — among a limited number of such certified centers in Poland — and operates a robotic surgery program (da Vinci system) for prostate, colorectal, and endometrial cancers, including a national first in certified robotic gynecology surgical assistance.
The underlying technology stack combines da Vinci-class robotic surgical platforms, advanced endoscopic imaging (colonoscopy, gastroscopy, EUS, ESD, POEM), diagnostic imaging (CT, MRI, ultrasound, mammography with tomosynthesis), and clinical laboratory diagnostics including histopathology and genetic profiling. Multidisciplinary care is delivered through dedicated breast, colorectal, prostate, and endometrial cancer coordinators, with a Primary Nursing model implemented since 2017. The organization's revenue model is primarily NFZ reimbursement across hospital services, outpatient specialist care, diagnostics, and rehabilitation, supplemented by commercial private-pay services for non-NFZ-covered treatments and imaging. Clinical trials are offered free of charge under Bioethics Committee approval, providing patient access to investigational therapies without direct revenue capture. Distribution is direct through owned facilities, with patient access via GP/specialist referrals, the DILO fast-track oncology card, the central infoline, online contact forms, and self-referral for screening programs. The organization is accredited by the Minister of Health and has received EU funding through the Polish Recovery Plan (KPO) for infrastructure modernization.
LUX MED Onkologia – Szpital Szamocka firmographics
Firmographics- Name
- LUX MED Onkologia – Szpital Szamocka
- Legal name
- LUX MED Onkologia sp. z o.o.
- Website
- https://onkologia.luxmed.pl
- Company type
- Private
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- LUX MED Onkologia is a private Polish oncology hospital network operating six facilities across Warsaw and Łódź, providing NFZ-funded cancer diagnosis, robotic and surgical oncology, chemotherapy, immunotherapy, endoscopy, and rehabilitation under specialized BCU and CCU designations.
- Ownership category
- akta.pro rank
LUX MED Onkologia – Szpital Szamocka industry classification
Industry- Product category
- Oncology Hospital Services
- NAICS
- Specialty (except Psychiatric and Substance Abuse) Hospitals (62231), Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), Specialty (except Psychiatric and Substance Abuse) Hospitals (6223), Diagnostic Imaging Centers (621512)
- SIC
- Services-Hospitals (8060), Services-Health Services (8000), Services-Specialty Outpatient Facilities, Nec (8093)
- akta.pro primary industry
- Oncology & Cancer Specialty Hospitals (HLAFAHAC)
- akta.pro secondary industries
- Surgical Oncology (HLAKAFAG), Gynecologic Oncology & Women’s Cancer Centers (HLAFAJAK)
Keywords
Where LUX MED Onkologia – Szpital Szamocka is headquartered
LocationHeadquarters
- HQ city
- Warszawa, Mazowieckie
- HQ country
- Poland
- HQ region
- Europe
Offices6 records
Markets served
LUX MED Onkologia – Szpital Szamocka business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain
Revenue model
- NFZ (Narodowy Fundusz Zdrowia) Reimbursement: Primary revenue stream from government-mandated public health insurance reimbursements. All citizens covered by universal health insurance receive diagnostic and therapeutic oncology services at LUX MED Onkologia under the same conditions as public hospitals, in a private hospital setting. Covers all treatment modalities including surgery, chemotherapy, immunotherapy, hormone therapy, radiotherapy, and diagnostic procedures.
- Commercial / Private Pay Services: Supplementary revenue from privately funded medical services not covered by NFZ or commercial versions of diagnostic and treatment services. Includes specialist outpatient consultations, certain imaging modalities (e.g., mammography with tomosynthesis), and potentially experimental treatments outside drug program coverage.
- Clinical Trials (Badania Kliniczne): Free-of-charge access to investigational treatments through participation in clinical trials, approved by Bioethics Committee and registered in Central Clinical Trials Registry. Generates no direct revenue but provides early access to innovative therapies.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Multi-year contract | NFZ-funded oncology services (public healthcare) |
| Other | Pay-as-you-go | Commercial / private services |
Go-to-market motion1 record
Distribution channels5 records
Marketing channels5 records
LUX MED Onkologia – Szpital Szamocka product offering
Product offeringCore offering
LUX MED Onkologia operates a network of specialized oncology hospitals in Warsaw and Łódź, Poland, providing comprehensive cancer diagnosis and treatment. Core services include surgical oncology with da Vinci robotic-assisted surgery for prostate, colorectal, and endometrial cancers, clinical oncology (chemotherapy, immunotherapy, hormone therapy, targeted therapies), advanced diagnostic imaging (CT, MRI, mammography with tomosynthesis), endoscopic procedures, NFZ-funded screening programs, drug programs, clinical trials, and supportive care including psycho-oncology, dietetics, and rehabilitation.
Product overview
LUX MED Onkologia is a network of specialized oncology hospitals in Warsaw and Łódź, Poland, providing comprehensive cancer diagnosis and treatment services under NFZ (National Health Fund) agreements. The network comprises six facilities: Szpital Szamocka (main clinical oncology and chemotherapy hospital), Szpital św. Wincentego (robotic surgery center), Szpital Fieldorfa (clinical oncology), Szpital św. Elżbiety (robotic surgery and cardiology), Endoterapia in Łódź (endoscopy), and Centrum Rehabilitacji (rehabilitation). Services include surgical oncology with advanced robotic surgery using the da Vinci system for colorectal, prostate, and endometrial cancers; clinical oncology with chemotherapy, immunotherapy, and hormone therapy; comprehensive diagnostic imaging; cancer prevention screening programs (mammography, colonoscopy, cytology); drug programs providing access to modern therapies; clinical trials; and supportive care including psycho-oncology, dietetics, and rehabilitation. The network is recognized as one of the leaders in oncology surgery rankings in Poland and operates specialized competency centers for breast cancer (Breast Cancer Unit) and colorectal cancer (Colorectal Cancer Unit).
Differentiator
Problem solved
Functional benefit
Products and services
- Szpital Szamocka
- Szpital św. Wincentego
- Szpital Fieldorfa
- Szpital św. Elżbiety
- Endoterapia (Łódź)
- Centrum Rehabilitacji
- Robotic Surgery (Chirurgia Robotyczna)
- Clinical Oncology and Chemotherapy
- Fast Track Oncology (Szybka Terapia Onkologiczna)
- Clinical Trials (Badania Kliniczne)
- Drug Programs (Programy Lekowe)
- Cancer Prevention Programs (Profilaktyka Nowotworów)
- Diagnostic Imaging (Diagnostyka Obrazowa)
- Psychological Support (Wsparcie Psychologiczne)
- Dietetic Services (Dietetyk)
Quantifiable outcome
- NFZ-funded robotic surgery reduces hospital stay to as little as 1-2 days post-operatively for endometrial cancer patients
- +2 more outcomes
Companies that use LUX MED Onkologia – Szpital Szamocka
Customer profileNamed customers5 records
Segments7 records
Ideal customer profiles2 records
LUX MED Onkologia – Szpital Szamocka technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
LUX MED Onkologia – Szpital Szamocka partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered minor.
- Fundacja OnkoCafe (OnkoCafe Foundation)minorFundacja OnkoCafe is a patient support foundation. LUX MED Onkologia partners with the foundation to provide additional support services and resources for oncology patients. The partnership appears in the 'Nasi partnerzy' (Our partners) section of the website.
- Narodowy Instytut Onkologii (National Oncology Institute – NIO)minorNarodowy Instytut Onkologii (NIO) – National Oncology Institute (Poland) is listed as a partner in the 'Nasi partnerzy' section. NIO serves as the premier national reference center for cancer research, treatment guidelines, and professional training in Poland.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
LUX MED Onkologia – Szpital Szamocka competitors and assessment
Company assessmentBroad incumbents
- Medicover: Major private healthcare operator in Poland and Central Europe offering integrated hospitals, clinics, and diagnostics. Comparable as a peer parent/operator and competes for NFZ-funded specialty volumes, though oncology is not its core focus.
- Charité Comprehensive Cancer Center: Major academic cancer center in Berlin operating as a designated oncology center of excellence. Comparable as a peer benchmark for BCU/CCU-style specialist center accreditation, multidisciplinary care, and integration with clinical research.
- Enel-Med: One of Poland's largest private healthcare networks, offering outpatient and inpatient services under NFZ and commercial contracts. Overlaps with LUX MED Onkologia as a private-sector NFZ contractor in specialty and diagnostic services.
Direct peers
- Affidea Poland: Pan-European private operator of diagnostic and cancer treatment centers with significant Polish footprint. Overlaps with LUX MED Onkologia in oncology diagnostics, imaging, and outpatient oncology services, often competing for NFZ contracts in oncology-adjacent specialties.
- GenesisCare: Global private cancer care operator with European presence, specializing in radiotherapy, medical oncology, and advanced diagnostics. Comparable as a private-sector cancer specialty provider scaling across multiple geographies with technology-driven treatment.
- Maria Skłodowska-Curie National Research Institute of Oncology (NIO/COI): Poland's premier state-run oncology reference center, listed as a partner on LUX MED Onkologia's website. Provides the full continuum of cancer care under NFZ and competes directly for specialist oncology volumes, particularly in complex and hematological cases.
- Istituto Europeo di Oncologia (IEO): Leading European private nonprofit cancer specialty hospital in Milan. Comparable as a model for comprehensive cancer-only hospital operations with multidisciplinary specialist units, research integration, and advanced surgical oncology including robotics.
- NU-MED Group: Polish private oncology hospital network operating multiple cancer treatment centers across Poland. Direct competitor offering chemotherapy, radiotherapy, and surgical oncology under NFZ contracts, overlapping closely with LUX MED Onkologia's service mix and payer model.
Regional players
- Swissmed Centrum Zdrowia: Private hospital in Gdańsk offering multi-specialty inpatient services under NFZ. Comparable as a Polish private-sector NFZ-contracted hospital operator competing in select specialty and surgical markets outside Warsaw.
- Centrum Medyczne Damiana: Warsaw-based private healthcare operator offering specialist outpatient and surgical services under NFZ. Comparable as a Warsaw private-sector NFZ competitor in diagnostics, specialist consultations, and surgical specialties adjacent to oncology.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
LUX MED Onkologia – Szpital Szamocka social profiles
Digital presenceLUX MED Onkologia – Szpital Szamocka compliance and trust
Trust signalCompliance2 records
LUX MED Onkologia – Szpital Szamocka financial estimates
Financial estimateRevenue estimate
Valuation estimate
LUX MED Onkologia – Szpital Szamocka leadership team
Management profileNumber of profiles
Profiles2 records
LUX MED Onkologia – Szpital Szamocka funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
LUX MED Onkologia – Szpital Szamocka M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about LUX MED Onkologia – Szpital Szamocka
What does LUX MED Onkologia – Szpital Szamocka do?
LUX MED Onkologia operates a network of specialized oncology hospitals in Warsaw and Łódź, Poland, providing comprehensive cancer diagnosis and treatment. Core services include surgical oncology with da Vinci robotic-assisted surgery for prostate, colorectal, and endometrial cancers, clinical oncology (chemotherapy, immunotherapy, hormone therapy, targeted therapies), advanced diagnostic imaging (CT, MRI, mammography with tomosynthesis), endoscopic procedures, NFZ-funded screening programs, drug programs, clinical trials, and supportive care including psycho-oncology, dietetics, and rehabilitation.
Is LUX MED Onkologia – Szpital Szamocka a public or private company?
LUX MED Onkologia – Szpital Szamocka is a private company. It is classified as corporate owned and is currently operating.
When was LUX MED Onkologia – Szpital Szamocka founded?
LUX MED Onkologia – Szpital Szamocka was founded in 2005. It employs 1 to 10 people.
Where is LUX MED Onkologia – Szpital Szamocka based?
LUX MED Onkologia – Szpital Szamocka is headquartered in Warszawa, Mazowieckie, Poland, in the Europe region.
How does LUX MED Onkologia – Szpital Szamocka make money?
Three revenue lines are on record. NFZ (Narodowy Fundusz Zdrowia) Reimbursement is the primary driver. The others are commercial / Private Pay Services and clinical Trials (Badania Kliniczne).
Who are LUX MED Onkologia – Szpital Szamocka's main competitors?
Broad incumbents on record are Medicover, Charité Comprehensive Cancer Center and Enel-Med. Direct peers are Affidea Poland, GenesisCare, Maria Skłodowska-Curie National Research Institute of Oncology (NIO/COI), Istituto Europeo di Oncologia (IEO) and NU-MED Group. Regional players are Swissmed Centrum Zdrowia and Centrum Medyczne Damiana.
Does LUX MED Onkologia – Szpital Szamocka have an API?
No public API is recorded for LUX MED Onkologia – Szpital Szamocka.
What industry is LUX MED Onkologia – Szpital Szamocka in?
LUX MED Onkologia – Szpital Szamocka's product category is Oncology Hospital Services. Its primary akta.pro industry code is HLAFAHAC, Oncology & Cancer Specialty Hospitals, with a secondary code of HLAKAFAG, Surgical Oncology. Its NAICS code is 62231 and its SIC code is 8060.